Table 1.

The basic information of the included literature.

Study	Population	Study type	Country	Intervention	All person	controls	Vaccine efficacy(95%CI)	Injection-site pain	Adverse reactions
Walter et al.²	5–11years	Randomized controlled trial	United States	BNT162b2 mRNA	2268	750	90.7% (95% CI, 67.7–98.3)	1093	/
Frenck et al.³	12–15years	Randomized controlled trial	United States	BNT162b2 mRNA	2260	1129	100% (95% CI, 78.1 to 100)	939	/
Olson et al.⁴	12–18years	Randomized controlled trial	United States	Pfizer-BioNTech mRNA.2doses	464	285	93% (95% CI = 83–97%)	/	/
Hause et al.⁵	12–17years	observational study	United States	BNT162b2 mRNA	66,550	/	/	41,927	46,585
Freedman et al.⁶	12–15years	observational study	Israel	BNT162b2 mRNA	187,707	/	91.5% (95% CI 88.2–93.9%	/	/
Ali et al.⁷	12–17years	Randomized controlled trial	United States	mRNA-1273	3732	1243	98.8(95%CI= 97.0 to 99.7)	2290	2140
Han et al.⁸	3–17 years	Randomized controlled trial	China	CoronaVac	333	114	96•8% [95%CI= 93•1–98•8]	35	59
Zhu et al.⁹	6–17years	Randomized controlled trial	China	Recombinant Adenovirus Type-5–Vectored Coronavirus	150	50	98.0% (95%CI= 93.0–99.5)	50	82
Xia et al.¹⁰	3–17years	Randomized controlled trial	China	BBIBP-CorV	810	90	100%	53	229